Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 2, 2000, Pages 127-137

  Kelloff, Gary J ^a   Sigman, Caroline C ^b   Johnson, Karen M ^a   Boone, Charles W ^a   Greenwald, Peter ^a   Crowell, James A ^a   Hawk, Ernest T ^a   Doody, Linda A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BIOLOGICAL MARKER; ESTROGEN; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CARCINOMA IN SITU; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; GENE AMPLIFICATION; GENOME; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; DRUG DESIGN; HUMANS; NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033999727     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Kelloff, G. J., Johnson, J. R., Crowell, J. A., Boone, C. W., DeGeorge, J. J., Steele, V. E., Mehta, M. U., Temeck, J. W., Schmidt, W. J., Burke, G., Greenwald, P., and Temple, R. J. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomark. Prev., 4: 1-10, 1995.
2. Kelloff, G. J., Boone, C. W., Steele, V. E., Crowell, J. A., Lubet, R., and Sigman, C. C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 54: 2015S-2024S, 1994.
3. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Doody, L. A. Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials. J. Cell. Biochem., 19: 1-9, 1994.
4. Lippman, S. M., Benner, S. E., and Hong, W. K. Cancer chemoprevention. J. Clin. Oncol., 12: 851-883, 1994.
5. Kelloff, G. J., Hawk, E. T., Crowell, J. A., Boone, C. W., Nayfield, S. G., Perloff, M., Steele, V. E., Lubet, R. A., and Sigman, C. C. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Huntington), 10: 1471-1480, 1484, 1996.
6. Kelloff, G. J., Hawk, E. T., Karp, J. E., Crowell, J. A., Boone, C. W., Steele, V. E., Lubet, R. A., and Sigman, C. C. Progress in clinical chemoprevention. Semin. Oncol., 24: 1-13, 1997.
7. Hong, W. K., and Sporn, M. B. Recent advances in chemoprevention of cancer. Science (Washington DC), 278: 1073-1077, 1997.
8. Frykberg, E. R., and Bland, K, I. In situ breast carcinoma. Adv. Surg., 26: 29-72, 1993.
9. Page, D. L., Dupont, W. D., Rogers, L. W., and Rados, M. S. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (Phila.), 55: 2698-2708, 1985.
10. Bruzzi, P., Bonelli, L., Costantini, M., Sciallero, S., Boni, L., Aste, H., Gatteschi, B., Naldoni, C., Bucchi, L., Casetti, T., Bertinelli, E., Lanzanova, G., Onofri, P., Parri, R., Rinaldi, P., Castiglione, G., Mantellini, P., and Giannini, A. A multicenter study of colorectal adenomas - rationale, objectives, methods and characteristics of the study cohort. Tumori, 81: 157-163, 1995.
11. Day, D. W., and Morson, B. C. The adenoma-carcinoma sequence. In: Bennington, J. L. (ed.), The Pathogenesis of Colorectal Cancer., Vol. 10, Chap. 6, pp. 58-71. Philadelphia, PA: W. B. Saunders Co., 1978.
12. Bostwick, D. G. Prostatic intraepithelial neoplasia (PIN): current concepts. J. Cell. Biochem., 16H: 10-19, 1992.
13. Califano, J., van der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D., Greenberg, B., Koch, W., and Sidransky, D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res., 56: 2488-2492, 1996.
14. Sporn, M. B. The war on cancer. Lancet, 347: 1377-1381, 1996.
15. Schipper, H., Turley, E. A., and Baum, M. A new biological framework for cancer research. Lancet, 348: 1149-1151, 1996.
16. Bissell, M. J., Weave, r. V. M., Lelievre, S. A., Wang, F., Petersen, O. W., and Schmeichel, K. L. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res., 59: 1757s-1764s, 1999.
17. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
18. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M. L., Cavenee, W., and Vogelstein, B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (Lond.), 555: 846-847, 1992.
19. Sidransky, D., and Messing, E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. Urol. Clin. North Am., 19: 629-639, 1992.
20. Sidransky, D., Frost, P., Von Eschenbach, A., Oyasu, R., Preisinger, A. C., and Vogelstein, B. Clonal origin bladder cancer. N. Engl. J. Med., 326: 737-740, 1992.
21. Rosin, M. P., Cairns, P., Epstein, J. I., Schoenberg, M. P., and Sidransky, D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res., 55: 5213-5216, 1995.
22. Mao, L., Schoenberg, M. P., Scicchitano, M., Erozan, Y. S., Merlo, A., Schwab, D., and Sidransky, D. Molecular detection of primary bladder cancer by microsatellite analysis. Science (Washington DC), 271: 659-662, 1996.
23. Simoneau, A. R., and Jones, P. A. Bladder cancer: the molecular progression to invasive disease. World J. Urol., 12: 89-95, 1994.
24. Thiberville, L., Payne, P., Vielkinds, J., LeRiche, J., Horsman, D., Nouvet, G., Palcic, B., and Lam, S. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res., 55: 5133-5139, 1995.
25. Kishimoto, Y., Sugio, K., Hung, J. Y., Virmani, A. K., McIntire, D. D., Minna, J. D., and Gazdar, A. F. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J. Natl. Cancer Inst., 87: 1224-1229, 1995.
26. Larson, A. A., Liao, S-Y., Stanbridge, E. J., Cavenee, W. K., and Hampton, G. M. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res., 57: 4171-4176, 1997.
27. Boone, C. W., Kelloff, G. J., and Steele, V. E. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res., 52: 1651-1659, 1992.
28. Muto, T., Bussey, H. J. R., and Morson, B. C. The evolution of cancer of the colon and rectum. Cancer (Phila.), 36: 2251-2270, 1975.
29. Hamilton, S. R. The adenoma-adenocarcinoma sequence in the large bowel: variations on a theme. J. Cell. Biochem., 16 (Suppl. G): 41-46, 1992.
30. Hamilton, S. R. Pathology and biology of colorectal neoplasia. In: Young, G. P., Levin, B., and Rozen, P. (eds.), Prevention and Early Detection of Colorectal Cancer: Principles and Practice, pp. 3-21. London, England: W. B. Saunders, 1996.
31. Slaughter, D. P., Southwick, H. W., and Smejkal, W. 'Field cancerization' in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer (Phila.), 6: 963-968, 1953.
32. Benner, S. E., Hong, W. K., Lippman, S. M., Lee, J. S., and Hittelman, W. M. Intermediate biomarkers in upper aerodigeslive tract and lung chemoprevention trials. J. Cell. Biochem., 16G: 33-38, 1992.
33. Hittelman, W. N., Kim, H. J., Lee, J. S., Shin, D. M., Lippman, S. M., Kim, J., Ro, J. Y., and Hong, W. K. Detection of chromosome instability of tissue fields at risk: in situ hybridization. J. Cell. Biochem., (Suppl. 25): 57-62, 1996.
34. Hjermann, I., Velve Byre, K., Holme, I., and Leren, P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial of healthy men. Lancet, 2: 1303-1310, 1981.
35. Dhingra, K., Sneige, N., Pandita, T. K., Johnston, D. A., Lee, J. S., Emani, K., Hortobagyi, G. N., and Hittelman, W. N. Quantitative analysis of chromosome in situ hybridization signal in paraffin-embedded tissue sections. Cytometry, 16: 100-112, 1994.
36. Segers, P., Haesen, S., Castelain, P., Amy, J-J., De Sutter, P., Van Dam, P., and Kirsch-Volders, M. Study of numerical aberrations of chromosome 1 by fluorescent in situ hybridization and DNA content by densitometric analysis on (pre)-malignant cervical lesions. Histochem. J., 27: 24-34, 1995.
37. Soloway, M. S., and Perito, P. E. Superficial bladder cancer: diagnosis, surveillance and treatment. J. Cell. Biochem., 161 (Suppl.): 120-127, 1992.
38. Herr, H. W., Jakse, G., and Sheinfeld, J. The T1 bladder tumor. Semin. Urol., 8: 254-261, 1990.
39. Harris, A. L., and Neal, D. E. Bladder cancer - field versus clonal origin. N. Engl. J. Med., 326: 759-761, 1992.
40. Winawer, S. J., Zauber, A. G., O'Brien, M. J., Ho, M. N., Gottlieb, L., Sternberg, S. S., Waye, J. D., Bond, J., Schapiro, M., Stewart, E. T., Panish, J., Ackroyd, F., Kurtz, R. C., and Shike, M. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N. Engl. J. Med., 328: 901-906, 1993.
41. Burt, R. W. Cohorts with familial disposition for colon cancers in chemoprevention trials. J. Cell. Biochem., (Suppl. 25): 131-135, 1996.
42. Fabian, C. J., Kamel, S., Zalles, C., and Kimler, B. F. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J. Cell. Biochem., (Suppl. 25): 112-122, 1996.
43. Mulder, J-W. R., Offerhaus, G. J. A., de Feyter, E. P., Floyd, J. J., Kern, S. E., Vogelstein, B., and Hamilton, S. R. The relationship of quantitative nuclear morphology to molecular genetic alterations in the adenoma-carcinoma sequence of the large bowel. Am. J. Pathol., 141: 797-804, 1992.
44. Brown, P. O., and Botstein, D. Exploring the new world of the genome with DNA microarrays. Nature Gen., 21 (Suppl.): 33-37, 1999.
45. Eisen, M. B., Spellman, P. T., Brown, P. O., and Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA, 95: 14863-14868, 1998.
46. Mellors, J. W., Rinaldo, C. R., Jr., Gupta, P., White, R. M., Todd, J. A., and Kingsley, L. A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (Washington DC), 272: 1167-1170, 1996.
47. Saag, M. S., Holodniy, M., Kuritzkes, D. R., O'Brien, W. A., Coombs, R. Poscher, M. E., Jacobsen, D. M., Shaw, G. M., Richman, D. D., and Volberding, P. A. HIV viral load markers in clinical practice. Nat. Med., 2: 625-629, 1996.
48. Fleming, T. R., and DeMets, D. L. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med., 125: 605-613, 1996.
49. Temple, R. J. A regulatory authority's opinion about surrogate endpoints. In: Nimmo, W. S., and Tucker, G. T. (eds.), Clinical Measurement in Drug Evaluation, pp. 3-22. New York: John Wiley & Sons, 1995.
50. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J. Am. Med. Assoc., 269: 3015-3023, 1993.
51. Sahni, R., Maniet, A. R., Voci, G., and Banka, V. S. Prevention of restenosis by lovastatin after successful angioplasty. Am. Heart J., 121: 1600-1608, 1991.
52. Fail, P. S., Sahni, R. C., Maniet, A. R., Voci, G., and Banka, V. S. The long-term clinical efficacy of lovastatin therapy following successful coronary angioplasty. Clin. Res., 40: 400A, 1992.
53. Pitt, B., Ellis, S. G., Mancini, J., Rosman, H. S., and McGovern, M. E. for the PLAC 1 Investigators. Design and recruitment in the United States of a multi-center quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC 1). Am. J. Cardiol., 72: 31-35, 1993.
54. Crouse, J. R., Byington, R. P., Bond, M. G., Espeland, M. A., Sprinkle, J. W., McGovern, M., and Furberg, C. D. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control Clin. Trials, 13: 495-506, 1992.
55. Frick, M. H., Elo, O.. Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., Mäenpää, H., Mälkönen, M., Mänttäri, M., Norola, S., Pasternack, A., Pikkarainen, J., Romo, M., Sjöblom, T., and Nikkilä, E. A. Helsinki Heart Study. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med., 317: 1237-1245, 1987.
56. Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., and Furberg, C. D. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation, 91: 2274-2282, 1995.
57. Dayton, S., Pearce, M. L., Goldman, H., Harnish, A., Plotkin, D., Shickman, M., Winfield, M., Zager, A., and Dixon, W. J. Controlled trial of a diet high in unsaturated fat for prevention of atherosclerotic complications. Lancet, 2: 1060-1062, 1968.
58. Burr, M. L., Fehily, A. M., Gilbert, J. F., Rogers, S., Holliday, R. M., Sweetnam, P. M., Elwood, P. C., and Deadman, N. M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet, 2: 757-761, 1989.
59. Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., Jr., Sawin, H. S., Jr., Campos, C. T., Hansen, B. J., Tuna, N., Karnegis, J. N., Sanmarco, M. E., Amplatz, K., Castaneda-Zuniga, W. R., Hunter, D. W., Bissett, J. K., Weber, F. J., Stevenson, J. W., Leon, A. S., Chalmers, T. C., and the POSCH Group. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH): effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. New Engl. J. Med., 323: 946-955, 1990.
60. Wilhelmsen, L., Berglund, G., Elmfeldt, D., Tibblin, G., Wedel, H., Pennert, K., Vedin, A., Wilhelmsson, C., and Werkö, L. The multifactorial primary prevention trial in Göteborg, Sweden. Eur. Heart J., 7: 279-288, 1986.
61. Miettinen, T. A., Huttunen, J. K., Naukkarinen, V., Strandberg, T., Mattila, S., Kumlin T., and Sarna, S. Multifactorial primary prevention of cardiovascular diseases in middle-aged men: risk factor changes, incidence, and mortality. J. Am. Med. Assoc., 255: 2097-2102, 1982.
62. 1. Temple, R. Are surrogate markers adequate to assess cardiovascular disease drugs? J. Am. Med. Assoc., 282: 790-795, 1999.
63. Blue, J. W., and Colburn, W. A. Efficacy measures: surrogates or clinical outcomes? J. Clin. Pharmacol., 36: 767-770, 1996.
64. Wittes, J., Lakatos, E., and Probstfield, J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat. Med., 8: 415-425, 1989.
65. Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., Huther, M. L., Richardson, D. W., and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecanide, or placebo. New Engl. J. Med., 324: 781-788, 1991.
66. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the ant arrhythmic agent moricizine on survival after myocardial infarction. N. Engl. J. Med., 327: 227-233, 1992.
67. Marra, G., and Boland, C. R. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J. Natl. Cancer Inst., 87: 1114-1125, 1995.
68. Lynch, H. T., and Smyrk, T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). Cancer (Phila.), 76: 1149-1167, 1996.
69. Lipkin, M. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res., 48: 235-245, 1988.
70. Roth, J. A., Putnam, J. B., Jr., Rich, T. A., and Forastiere, A. Cancers of the gastrointestinal tract: cancer of the esophagus. In: DeVita, V. T., Jr., Hellman, S., and Rosenberg, S. A. (eds.), Cancer: Principles & Practice of Oncology, 5th ed., pp. 970-1251. Philadelphia: Lippincott-Raven Publishers, 1997.
71. Linehan, W. M., Cordon-Cardo, C., and Isaacs, W. Cancers of the genitourinary tract. In: DeVita, V. T., Jr., Hellman, S., and Rosenberg, S. A. (eds.), Cancer: Principles & Practice of Oncology, 5th ed., pp. 1253-1395. Philadelphia: Lippincott-Raven Publishers, 1997.
72. Mulshine, J. L., Linnoila, R. I., Jensen, S. M., Magnani, J. L., Tockman, M. S., Gupta, P. K., Scott, F. S., Avis, I., Quinn, K., Birrer, M. J., Treston, A. M., and Cuttitta, F. Rational targets for the early detection of lung cancer. J. Natl. Cancer Inst. Monogr., 13: 183-190, 1992.
73. Peters, E. J., Morice, R., Benner, S. E., Lippman, S., Lukeman, J., Lee, J. S., Ro, J. Y., and Hong, W. K. Squamous metaplasia of the bronchial mucosa and its relationship to smoking. Chest, 103: 1429-1432, 1993.
74. Husgafvel-Pursiainen, K., Ridanpaa, M., Anttila, S., and Vainio, H. p53, and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J. Occup. Med., 37: 69-76, 1995.
75. Cotran, R. X., Kumar, V., and Robbins, S. L. (eds.), Robbins Pathologic Basis of Disease, 4th ed., pp. 1090-1094. Philadelphia, PA: W. B. Saunders Company, 1989.
76. Chanen, W. The CIN saga. The biological and clinical significance of cervical intraepithelial neoplasia. Aust. N. Z. J. Obstet. Gynaecol., 30: 18-23, 1990.
77. Ovaska, J., Miettinen, M., and Kivilaakso, E. Adenocarcinoma arising in Barrett's esophagus. Dig. Dis. Sci., 34: 1336-1339, 1989.
78. Williamson, W. A., Ellis, F. H., Jr., Gibb, S. P., Shahian, D. M., Aretz, H. T., Heatley, G. J., and Watkins, E., Jr. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch. Intern. Med., 151: 2212-2216, 1991.
79. Miros, M., Kerlin, P., and Walker, N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut, 32: 1441-1446, 1991.
80. Cameron, A. J., and Lomboy, C. T. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology, 103: 1241-1245, 1992.
81. Jankowski, J., Hopwood, D., Pringle, R., and Wormsley, K. G. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. Am. J. Gastroenterol., 88: 402-408, 1993.
82. Falk, G. W., and Richter, J. E. Reflux disease and Barrett's esophagus. Endoscopy, 28: 13-21, 1996.
83. Grisham, J. W. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis (Lond.), 18: 59-81, 1997.
84. Kannel, W. B., Castelli, W, P., Gordon, T., and McNamara, P. M. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. Intern. Med., 74: 1-12, 1971.
85. Qian, J., Bostwick, D. G., Takahashi, S., Borell, T. J., Herath, J. F., Lieber, M. M., and Jenkins, R. B. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res., 55: 5508-5514, 1995.
86. Malins, D. C., Polissar, N. L., and Gunselman, S. J. Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH), and adenocarcinoma and have a high potential for predicting BPH and prostate cancer. Proc. Nat. Acad. Sci. USA, 94: 259-264, 1997.
87. Boyd, N. F., Byng, J. W., Jong, R. A., Fishell, E. K., Little, L. E., Miller, A. B., Lockwood, G. A., Tritchler, D. L., and Yaffe, M. J. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J. Natl. Cancer Inst., 87: 670-675, 1995.
88. Torrisi, R., Pensa, F., Orengo, M. A., Catsafados, E., Ponzani, P., Boccardo, F., Costa, A., and Decensi, A. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res., 53: 4769-4771, 1993.
89. Friedl, A., Jordan, V. C., and Pollak, M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen ther-apy. Eur. J. Cancer, 29A: 1368-1372, 1993.
90. Mao, L., Fan, Y-H., Lotan, R., and Hong, W. K. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res., 56: 5128-5131, 1996.
91. Sozzi, G., Sard, L., De Gregorio, L., Marchetti, A., Musso, K., Buttitta, F., Tornielli, S., Pellegrini, S., Veronese, M. L., Manenti, G., Incarbone, M., Chella, A., Angeletti, C. A., Pastorino, U., Huebner, K., Bevilaqua, G., Pilotti, S., Croce, C. M., and Pierotti, M. A. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res., 57: 2121-2123, 1997.
92. Hemstreet, G. P., III, Rao, J. Y., Hurst, R. E., Bonner, R. B., Jones, P. L., Vaidya, A. M., Fradet, Y., Moon, R. C., and Kelloff, G. J. Intermediate endpoint biomarkers for chemoprevention. J. Cell. Biochem., 161 (Suppl.): 93-110, 1992.
93. Hemstreet, G. P., III, Rao, J. Y., Hurst, R. E., Bonner, R. B., Waliszewski, P., Grossman, H. B., Liebert, M., and Bane, B. L. G-Actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. J. Cell. Biochem. (Suppl. 25): 197-204, 1996.
94. Boiko, I. V., Mitchell, M. F., Pandey, D. K., White, R. A., Hu, W., Malpica, A., Nishioka, K., Boone, C. W., Atkinson, E. N., and Hittelman, W. N. DNA image cytometric measurement as a surrogate end point biomarker in a Phase I trial of α-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol., Biomark. Prev., 6: 849-856, 1997.
95. Nelson, M. A., Einspahr, J. G., Alberts, D. S., Balfour, C. A., Wymer, J. A., Welch, K. L., Salasche, S. J., Bangert, J. L., Grogan, T. M., and Bozzo, P. O. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett., 85: 23-29, 1994.